FDA Approves 12-Month Flea Treatment for Dogs
Federal agency authorizes first-ever long-acting injectable parasite prevention
The U.S. Food and Drug Administration has approved Bravecto Quantum, the first injectable flea and tick preventative offering up to 12 months of protection for dogs. Announced on Thursday, this veterinary breakthrough provides an alternative to traditional monthly or quarterly treatments for dogs and puppies 6 months and older. The medication represents a significant advancement in pet parasite control options available to American pet owners.
The newly approved treatment contains fluralaner as its active ingredient, which belongs to the isoxazoline class of medications commonly used in parasite prevention. Licensed veterinarians must administer the injection and will determine whether an 8 or 12-month protection period is appropriate based on local tick species. Veterinarians will also monitor patients for potential side effects, which may include neurological issues such as muscle tremors and seizures in some dogs.
KEY POINTS
- •FDA approves 12-month flea treatment
- •Must be administered by veterinarians
- •First injectable long-term protection
The FDA's approval provides a convenient option for dog owners who live in regions requiring year-round parasite protection or who struggle with consistent administration of more frequent treatments. Dr. Tina Wismer, senior director of toxicology at ASPCA Poison Control, noted that the long-term preventative could be particularly useful in certain geographic areas where continuous protection is necessary. The treatment is manufactured by Intervet, Inc., based in Rahway, New Jersey.
Pet health advocates have responded to the new treatment with measured enthusiasm. Julie Cappiello from Voters For Animal Rights acknowledged the convenience of the long-lasting preventative while emphasizing that individual assessment remains important. Health professionals recommend that pet owners consult with their veterinarians to determine if this treatment is appropriate for their dogs, particularly those with a history of neurological conditions.
The approval comes as seasonal concerns about parasites increase with warmer weather across the United States. The FDA's authorization of this new treatment option expands the tools available to veterinarians and pet owners for managing flea and tick infestations, which can cause significant health problems in dogs if left untreated. The development represents a notable advancement in veterinary medicine's approach to parasite control.